NeurAxis, Inc. NRXS

Company Overview

NeurAxis, Inc. is a U.S.-based medical technology company focused on neuromodulation therapies for chronic and debilitating conditions, primarily in pediatric and adolescent patient populations. The company operates in the healthcare and medical device industries and is best known for commercializing the IB-Stim device, a percutaneous electrical nerve field stimulation (PENFS) therapy cleared by the U.S. Food and Drug Administration for functional abdominal pain associated with irritable bowel syndrome (IBS) in patients aged 8 to 21 years. Revenue has historically been driven primarily through sales of the IB-Stim device and related treatment procedures to healthcare providers specializing in gastroenterology and pediatric care.

NeurAxis originated from technology developed to address disorders influenced by the autonomic nervous system and has evolved into a focused neuromodulation company targeting conditions with limited pharmaceutical treatment alternatives. The company has positioned itself within a specialized segment of non-drug pain management and gastrointestinal treatment, emphasizing minimally invasive therapy and physician-supervised outpatient use. Its strategic differentiation is tied to FDA-cleared technology, clinical validation in pediatric gastrointestinal disorders, and reimbursement expansion efforts with commercial insurers and government healthcare programs.